Detall de la convocatòria


Objectiu de la convocatòria
Funding for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.
Característiques principals
For the 2022-2023 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:
  • Identifying biomarkers of response/resistance to targeted (i.e., b-RAF, MEK inhibitors) and immune therapeutics (i.e., immune checkpoint inhibitors including recently approved relatlimab)
  • Identifying specific biomarkers which may help to assess which patients with primary melanoma are at risk of metastatic disease and will benefit from adjuvant and/or neo-adjuvant therapies
  • Advancing non-T cell-based immunotherapy approaches (i.e., B cells, NK cells, macrophages, etc.) and other approaches examining the Tumor Microenvironment (TME) (stromal cells, fibroblasts, and other non-immune cells)
  • Discovering novel effective therapies (single agents and/or combinations) by repurposing drugs from other applications
  • Interrogating melanoma preclinical models with functional genomics and other technologies to identify new targets
  • Dissecting the molecular mechanisms of melanoma metastasis, with an emphasis on brain metastasis and leptomeningeal disease

    Types of awards:
  • Young Investigator Award: Scientists within five years of their first academic faculty appointment. A mentorship commitment from a senior investigator is required.
  • Established Investigator Award: Scientist past the initial five years of their first faculty appointment.
  • Established Investigator Academic-Industry Partnership Award: Projects co-funded by MRA and an industry partner whose involvement is essential to the project.
  • Pilot Award: Senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals

    Other special opportunities are described in the RFP document.
  • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, Ext.: 1670
    • Marta López, Ext.: 1576
    Convocatòria (URL)
    General eligibility requirements:
  • Principal Investigators (PIs) must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above at an academic or other non-profit research institution within or outside the United States.
  • PIs must be able to show clear evidence of an independent research program.
  • If previously funded by MRA, applicant must be up-to-date on all reporting requirements.
  • Fellows or those in other training or research support positions are not eligible to apply.
  • Individuals employed by state or federal government agencies may participate in research proposals as non-funded collaborators, but may not apply for MRA funding.
  • Investigators need not be specifically trained in melanoma research; however, they should be working in an environment capable of conducting high-quality, high-impact melanoma research.
  • An investigator may serve as PI on only one proposal submitted to MRA for any of the award mechanisms in this cycle. This includes any Special Opportunity Awards.
  • Mentors for Young Investigator Award applicants may serve as a PI on a separate proposal this cycle; however, that proposal must represent a distinct hypothesis from the Young Investigator’s proposal.
  • Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.
  • Dotació
  • Young Investigator Award: $85,000 per year for 3 years
  • Established Investigator Award: Up to $125,000 per year for three years
  • Established Investigator Academic-Industry Partnership Award: Up to $125,000 per year for three years. Industrial partner must provide funds or in-kind support
  • Pilot Award: $50,000 per year for 2 years
  • Durada
  • Young Investigator Award: 3 years
  • Team Science Award: 3 years
  • Team Science Academic-Industry Partnership Award: 3 years
  • Pilot Award: 2 years
  • Documentació
    Applicants must utilize the proposalCENTRAL online application tool at
    A detailed list of the documents to provide is given in the RFP document.
    Please note that each instrument has different deadlines:
  • October 5: Letters of Intent Due for RTFCCR-MRA Team Science Awards on Patient-Centered Clinical Trials
  • October 19: Young Investigator Award Eligibility Checklist Due
  • November 2: Full proposals due
  • Arxius